879883-54-2

Basic information

• Product Name: 4-Piperidin-4-ylmethyl-piperidine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-Piperidin-4-ylmethyl-piperidine-1-carboxylic acid tert-butyl ester;tert-Butyl 4-(piperidin-4-ylmethyl)piperidine-1-carboxylate
• CAS NO: 879883-54-2
• Molecular Formula: C₁₆H₃₀N₂O₂
• Molecular Weight: 282.4216
• Mol File: 879883-54-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 4-Piperidin-4-ylmethyl-piperidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Piperidin-4-ylmethyl-piperidine-1-carboxylic acid tert-butyl ester(879883-54-2)
• EPA Substance Registry System: 4-Piperidin-4-ylmethyl-piperidine-1-carboxylic acid tert-butyl ester(879883-54-2)

Safety Data

• Hazardous Substances Data: 879883-54-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Piperidin-4-ylmethyl-piperidine-1-carboxylic acid tert-butyl ester serves as a building block in the synthesis of various pharmaceutical agents due to its adaptable reactivity and functional groups. Its unique structure enables the creation of diverse chemical structures with potential medicinal properties, contributing to the development of new drugs and therapeutics.

Upstream product

• 1120-87-2 4-bromopyridin 
• 159635-49-1 tert-butyl 4-methylidenepiperidine-1-carboxylate 
• 333986-17-7 tert-butyl 4-(pyridin-4-ylmethyl)piperidine-1-carboxylate 

Relevant articles and documents

SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE

Bifunctional compounds, which find utility as modulators of non-receptor Leucine-rich repeat kinase 2 (LRRK2), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds LRRK2, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE

Bifunctional compounds, which find utility as modulators of leucine-rich repeat kinase 2 (LRRK2), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds LRRK2, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The hetero-bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

METHYLENE DIPIPERIDINE DERIVATIVES

The present invention relates to novel methylene dipiperidine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.